Rznomics

Rznomics develops RNA-based medicines, therapies that work by editing the genetic messages inside cells to treat disease.

It is a clinical-stage biotech listed on KOSDAQ, South Korea's tech-focused stock exchange. Its core platform uses a naturally occurring RNA enzyme, derived from a single-celled organism, that can seek out a disease-linked RNA target, cut it, and splice in a corrective gene sequence in a single step. The company's primary revenue model is licensing this platform technology to partners in exchange for upfront fees, development milestone payments, and royalties.